Prospective, randomized, controlled clinical study evaluating the efficacy of Rheopheresis for dry age-related macular degeneration
- 23 July 2009
- journal article
- research article
- Published by Springer Nature in Graefe's Archive for Clinical and Experimental Ophthalmology
- Vol. 247 (10) , 1297-1306
Abstract
To evaluate Rheopheresis for the treatment of patients with high-risk dry age-related macular degeneration and no therapeutic alternative. Rheopheresis is a method of therapeutic apheresis using the methodology of double filtration plasmapheresis to treat microcirculatory disorders. The dry AMD treatment with Rheopheresis trial (ART) was a randomised, controlled clinical study. Patients with the diagnosis of AMD in both eyes, with the study eye presenting dry AMD and soft drusen (the fellow eye had advanced AMD) were randomly assigned in a 1:1 ratio to receive ten Rheopheresis treatments within 17 weeks or to remain untreated. The primary outcome was change in best-corrected ETDRS-visual acuity (mean logMar change) after 7.5 months compared to baseline visual acuity for both groups. Forty-three eyes of 43 patients (22 treatment and 21 control group) were analysed. The mean baseline BCVA in study eyes was 0.58 in the treatment group and 0.66 in the control group (n.s. p = 0.19). At the primary efficacy endpoint 7.5 months post baseline, there was a statistically significant mean difference of 0.95 ETDRS lines (p = 0.01) between the Rheopheresis and control groups. Nine percent of eyes in the group treated with Rheopheresis gained 2 or more ETDRS lines, as compared with 0% of eyes with no treatment. None of the treated patients had a loss in visual acuity in their study eyes, as compared with 24% of patients without treatment who lost 1 ETDRS line or more; 19% lost 2 ETDRS lines or more. Rheopheresis treatment was safe and well-tolerated. The results of ART provide further evidence that Rheopheresis is a safe and effective therapeutic option for high-risk patients with dry AMD and no therapeutic alternative. A series of Rheopheresis treatments can improve the natural course of AMD for selected patients.Keywords
This publication has 29 references indexed in Scilit:
- Quality of Life in Patients With Idiopathic Sudden Hearing LossOtology & Neurotology, 2008
- Age-Related Macular DegenerationNew England Journal of Medicine, 2008
- The Natural History and Prognosis of Neovascular Age-Related Macular DegenerationOphthalmology, 2008
- ROLE OF GENETIC FACTORS AND INFLAMMATION IN AGE-RELATED MACULAR DEGENERATIONRetina, 2007
- Rheopheresis in Patients with Critical Limb Ischemia––Results of an Open Label Prospective Pilot TrialTherapeutic Apheresis and Dialysis, 2005
- Reduced Foveolar Choroidal Blood Flow in Eyes with Increasing AMD SeverityInvestigative Ophthalmology & Visual Science, 2005
- How big is the burden of visual loss caused by age related macular degeneration in the United Kingdom?British Journal of Ophthalmology, 2003
- Rheopheresis: Rheologic, Functional, and Structural AspectsTherapeutic Apheresis, 2000
- INFLUENCE OF MEMBRANE DIFFERENTIAL FILTRATION ON THE NATURAL COURSE OF AGE-RELATED MACULAR DEGENERATIONRetina, 2000
- Natural course in fellow eyes of patients with unilateral age‐related exudative maculopathyActa Ophthalmologica, 1993